SOURCE: Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc.

October 27, 2015 08:00 ET

Cleveland BioLabs to Report Third Quarter 2015 Financial Results on November 5

BUFFALO, NY--(Marketwired - Oct 27, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on November 5, 2015, it will report its financial results for the third quarter and nine-month period ended September 30, 2015, and will host a conference call at 10:00 a.m. ET. 

Interested parties may participate by dialing 877-407-9205 (US) or 201-689-8054 (International), approximately five to ten minutes before the call start time. A live webcast of the conference call will be available on the investor page of the Cleveland BioLabs website at

A replay of the call will be available starting on November 5, 2015, at 1:00 p.m. ET through November 19, 2015, at 11:59 p.m. ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering conference ID number 13622699. An archived webcast of the conference call will be available for 90 days on the Investors page of the Cleveland BioLabs website at

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. The company's proprietary platform of Toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's most advanced product candidate is entolimod, which is being developed for a biodefense indication and as an immunotherapy for oncology and other indications. The company conducts business in the United States and in the Russian Federation through a wholly-owned subsidiary, BioLab 612, LLC and a joint venture with OJSC Rusnano, Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at

Contact Information

  • Contact:
    Rachel Levine
    Vice President Investor Relations
    Cleveland BioLabs, Inc.
    T: (917) 375-2935